Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients
Brief Summary: This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection.

In severe COPD patients, sputum eosinophils levels are elevated similar as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD patients would translate into a reduction of COPD exacerbations. The study will determine the reduction in exacerbations in subjects who are above and below the baseline blood eosinophil count of at least 150 cells/microlitres. The study will evaluate the efficacy and safety of mepolizumab on the frequency of moderate and severe exacerbations in COPD subjects at high risk of exacerbations, despite the use of optimized standard of care background therapy.

Overall in this study, a total of 800 subjects will be randomised in 1:1 ratio to receive placebo or mepolizumab (100 milligram (mg)) administered SC. The total duration of this study will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
B: Arm Label: mepolizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mepolizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): mepolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Eosinophilic phenotype (EOS+) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS+ Benralizumab (2 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 2 mg | Arm Label: EOS+ Benralizumab (20 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 20 mg | Arm Label: EOS+ Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Arm Label: Non-eosinophil phenotype (EOS-) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS- Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: BIOLOGICAL; Name: Benralizumab 2 mg; Assigned to Arm(s): EOS+ Benralizumab (2 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 20 mg; Assigned to Arm(s): EOS+ Benralizumab (20 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): EOS+ Benralizumab (100 mg), EOS- Benralizumab (100 mg) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Eosinophilic phenotype (EOS+) Placebo, Non-eosinophil phenotype (EOS-) Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: D